Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EGFR | P00533 | 15/20 | 0.58 |
| ▸ | ERBB2 | P04626 | 15/20 | 0.56 |
| ▸ | ERBB3 | P21860 | 1/20 | 0.55 |
| ▸ | ERBB4 | Q15303 | 1/20 | 0.55 |
| ▸ | KDR | P35968 | 2/20 | 0.51 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.50 |
| ▸ | MET | P08581 | 1/20 | 0.49 |
| ▸ | LCK | P06239 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL937731 | 0.93 | EGFR (0.60) | EGFRERBB2ERBB3ERBB4KCNH2 | |
| SCHEMBL13074301 | 0.90 | EGFR (0.54) | EGFRERBB2KDRMET | |
| SCHEMBL10227851 | 0.85 | EGFR (0.60) | EGFRERBB2ERBB3ERBB4KCNH2 | |
| Hydrochloric Acid SCHEMBL2195262 | 0.85 | EGFR (0.59) | EGFRERBB2ERBB3ERBB4KCNH2 | |
| SCHEMBL938318 | 0.83 | STK3 (0.52) | EGFRERBB2ERBB3ERBB4KDR | |
| SCHEMBL12945014 | 0.82 | EGFR (0.56) | EGFRERBB2ERBB3ERBB4KDR | |
| SCHEMBL10227854 | 0.82 | EGFR (0.55) | EGFRERBB2ERBB3ERBB4KCNH2 | |
| Hydrochloric Acid SCHEMBL2196386 | 0.81 | EGFR (0.54) | EGFRERBB2ERBB3ERBB4KCNH2 | |
| SCHEMBL5629648 | 0.81 | EGFR (0.56) | EGFRERBB2ERBB3ERBB4KCNH2 | |
| SCHEMBL938557 | 0.81 | KDR (0.65) | EGFRKDRMET |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8501755-B2 | Tetrahydropyridothienopyrimidine compounds and methods of use thereof | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2013-08-06 | — | — | US | disclosed |
| US-8501755-B2 | Tetrahydropyridothienopyrimidine compounds and methods of use thereof | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2013-08-06 | — | — | US | disclosed |
| US-8501755-B2 | Tetrahydropyridothienopyrimidine compounds and methods of use thereof | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2013-08-06 | — | — | US | disclosed |
| EP-2001890-B1 | TETRAHYDROPYRIDOTHIENOPYRIMIDINE COMPOUNDS AND USE FOR THE TREATMENT OF CELL PROLIFERATIVE DISORDERS | BAYER SCHERING PHARMA AG (DE) | 2011-01-12 | — | — | EP | disclosed |
| EP-2001890-B1 | TETRAHYDROPYRIDOTHIENOPYRIMIDINE COMPOUNDS AND USE FOR THE TREATMENT OF CELL PROLIFERATIVE DISORDERS | BAYER SCHERING PHARMA AG (DE) | 2011-01-12 | — | — | EP | disclosed |
| US-20100298297-A1 | Tetrahydropyridothienopyrimidine Compounds and Methods of Use Thereof | BAYER HEALTHCARE AG (DE) | 2010-11-25 | — | — | US | disclosed |
| US-20100298297-A1 | Tetrahydropyridothienopyrimidine Compounds and Methods of Use Thereof | BAYER HEALTHCARE AG (DE) | 2010-11-25 | — | — | US | disclosed |
| WO-2007109279-A2 | TETRAHYDROPYRIDOTHIENOPYRIMIDINE COMPOUNDS AND METHODS OF USE THEREOF | BAYER HEALTHCARE AG (DE) | 2007-09-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100298297-A1 | Tetrahydropyridothienopyrimidine Compounds and Methods of Use Thereof | DPYD, TYMP, TPMT | EGFR 2580/4885ERBB2 1267/4885ERBB3 1624/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.